Black Friday Get Elite for just $149.00 Claim Now

Microbot Medical Reports Q3 Revenue of $72,000 as LIBERTY System Procedure Volumes Rise 44%

By Fiona Craig | November 16, 2026, 10:19 AM

Microbot Medical Inc. (NASDAQ:MBOT) reported third-quarter 2026 revenue of $72,000, down from $241,000 in the previous quarter, as the medical device company continued the commercial rollout of its LIBERTY Endovascular Robotic System.

In its Form 10-Q filing for the quarter ended September 30, 2026, Microbot attributed the revenue decline to the timing of customer reorders, seasonal factors and hospital purchasing approval processes, which typically take four to six months.

The company ended the quarter with 12 customer accounts, compared with 10 at the end of June, while procedure volumes involving the LIBERTY System increased 44% quarter on quarter.

Microbot also reported that all existing customers who had exhausted their initial inventory placed repeat orders for multiple systems.

Gross Margin Remains Negative as Manufacturing Costs Decline

Microbot reported a negative gross margin for the third quarter, with cost of goods sold increasing 24% sequentially.

The increase was primarily attributed to an inventory write-down and the sale of systems manufactured in earlier periods at higher production costs.

However, the company said manufacturing costs per unit continued to decline during the quarter as production efficiency improved.

Microbot expects further cost reductions from ongoing manufacturing initiatives and a planned second production line. The company believes these measures could support a positive gross margin during 2027, although this remains dependent on their successful implementation.

Customer Network Expands Across the United States

During the quarter, Microbot added an academic medical centre in North Carolina, bringing its customer base in the state to two healthcare systems.

The company also secured its first West Coast customer in California, which represents its first office-based laboratory account.

Microbot expanded its US sales network from eight to ten territories during the quarter and plans to increase coverage to 12 territories by the end of 2026.

The LIBERTY System has been used in several peripheral vascular procedures, including prostatic artery embolisation, Y-90 radioembolisation, genicular artery embolisation and uterine artery embolisation.

Israeli Distribution Agreement Supports International Expansion

Following regulatory approval from Israel’s Ministry of Health, Microbot entered into a three-year exclusive distribution agreement with Medtechnica Ltd. to market and sell the LIBERTY System in Israel.

The company expects to receive initial orders under the agreement during the fourth quarter of 2026.

Microbot also reported receiving additional patents in the United States, Japan, China and Canada during and after the reporting period.

Its intellectual property portfolio comprised 44 issued patents and 49 pending patent applications at the time of the announcement.

The company also completed its ISO certification surveillance audit.

Cash and Securities Total Approximately $62 Million

Microbot ended September with approximately $62 million in cash, cash equivalents and marketable securities.

The company said these resources would support its commercial expansion in the United States and international markets.

Harel Gadot, Microbot’s Chief Executive Officer, President and Chairman, commented on the company’s progress since the full market release of LIBERTY.

“While revenue this quarter in part reflected the seasonality of the third quarter and the sales cycle process associated with the VAC, we believe the progress we made this year positions us for several potential milestones over the coming months in the U.S. and the international markets in which we operate,” Gadot said.

The LIBERTY Endovascular Robotic System is an FDA-cleared, single-use robotic platform designed for remotely operated peripheral endovascular procedures.

Microbot’s near-term priorities include expanding hospital adoption, increasing procedure utilisation, developing its international distribution network and reducing manufacturing costs.

Microbot Medical stock price

Mentioned In This Article

Latest News

Nov-16
Nov-16
Nov-05
Oct-27
Oct-23
Oct-20
Oct-06
Sep-25
Aug-11
Jul-21
Jul-07
Jun-30
Jun-25
Jun-23
Jun-16